Teva announced that the U.S. Food and Drug Administration (FDA) approved WELTRUZA, a long-acting treatment for schizophrenia in adults. The new treatment is administered as a once-monthly subcutaneous injection. According to the company, it is the first and only treatment based on the active ingredient olanzapine to be administered monthly via subcutaneous injection.
The drug is expected to be available in the United States in the coming weeks, and it will be marketed in three different doses of 318, 425 and 531 milligrams, equivalent to daily doses of 10, 15 and 20 milligrams of oral olanzapine, respectively.

The new drug is based on olanzapine, an active ingredient used for more than 30 years to treat schizophrenia. The treatment is intended to address one of the most significant challenges in treating the disease: patients’ difficulty adhering to daily medication. According to Teva, the new treatment does not require loading doses, does not require supplemental oral medication and does not require medical monitoring after the injection.
What Did the Clinical Trial Results Show?
The approval was based on the results of an advanced Phase 3 clinical trial called SOLARIS. According to the company, the trial showed an improvement in disease symptoms, a reduction in severity and an improvement in patients’ personal and social functioning. The systemic safety profile observed was consistent with the known profile of oral olanzapine. However, the treatment involves risks and side effects.
The clinical trial reported, among other things, weight gain, drowsiness, headaches, constipation and injection-site reactions. Metabolic changes were also observed, consistent with the known safety profile of olanzapine, including the possibility of significant weight gain.

Teva’s Strategy and Expansion into Europe
Dr. Eric Hughes, executive vice president, head of global research and development and chief medical officer at Teva, said the approval reflects the company’s innovation and research capabilities. He said combining existing scientific knowledge with the development of a new formulation makes it possible to address a significant barrier in schizophrenia treatment and improve treatment options for people living with the disease.
The approval in the United States adds to Teva’s efforts to expand its activity in the central nervous system field and develop treatments with a distinct clinical advantage as part of the company’s growth strategy.
Alongside the approval in the United States, Teva continues to advance the approval process for a long-acting olanzapine-based treatment in Europe as well. The European Medicines Agency (EMA) accepted the marketing authorization application for the treatment in May 2026, but it has not yet been approved in Europe.










